Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Sionna Therapeutics, Inc. (SION)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND – Research Report) and Sionna Therapeutics, Inc. (SION – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ascendis Pharma (ASND)
In a report released today, Yun Zhong from Wedbush maintained a Buy rating on Ascendis Pharma, with a price target of $273.00. The company’s shares closed last Monday at $242.09.
According to TipRanks.com, Zhong has 0 stars on 0-5 stars ranking scale with an average return of
Ascendis Pharma has an analyst consensus of Strong Buy, with a price target consensus of $287.42, a 22.2% upside from current levels. In a report issued on February 17, Morgan Stanley also maintained a Buy rating on the stock with a $256.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Sionna Therapeutics, Inc. (SION)
TD Cowen analyst Ritu Baral maintained a Buy rating on Sionna Therapeutics, Inc. today. The company’s shares closed last Monday at $33.92.
According to TipRanks.com, Baral is a top 100 analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sionna Therapeutics, Inc. with a $50.33 average price target, a 53.0% upside from current levels. In a report issued on February 24, Citizens JMP also initiated coverage with a Buy rating on the stock with a $63.00 price target.
